iBio - Preclinical PD-1 Agonist Antibody Program - Ownership and Business Overview

Life ScienceCompany

iBio - Preclinical PD-1 Agonist Antibody Program Ownership

Who owns iBio - Preclinical PD-1 Agonist Antibody Program?

iBio - Preclinical PD-1 Agonist Antibody Program is owned by Otsuka Pharmaceutical. It was acquired on February 25, 2024.

iBio - Preclinical PD-1 Agonist Antibody Program Business Overview

Where is iBio - Preclinical PD-1 Agonist Antibody Program headquartered?

iBio - Preclinical PD-1 Agonist Antibody Program is headquartered in Bryan, Texas.

What sector is iBio - Preclinical PD-1 Agonist Antibody Program in?

iBio - Preclinical PD-1 Agonist Antibody Program is a life science company.

Life Science M&A Summary in 2024

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2024. The largest life science acquisition in 2024 was Catalent - which was acquired by Novo Holdings A/S for $16.5B.

Subscribe to Mergr to view all 221 acquisitions of life science companies in 2024, including 25 acquisitions by private equity firms, and 196 by strategics.

Acquired by Otsuka Pharmaceutical Co., Ltd. (Company) on 2024-02-25

iBio - Preclinical PD-1 Agonist Antibody Program

iBio - Preclinical PD-1 Agonist Antibody Program

Bryan, Texas 77807
United States,

iBio - Preclinical PD-1 Agonist Antibody Program is a pivotal checkpoint in the immune system, acting as a type of off switch that helps keep the cells from attacking other cells in the body. iBio's Preclinical PD-1 Agonist Antibody Program is based in Bryan, Texas.

Company Summary

SECTOR

Investor History
2024-02-25
Divestiture

53M USD

Otsuka Holdings

iBio

Subscribe to unlock this and 215,016
investor and company profiles

Sign-up today to get full access

Unlimited Searches
Unlimited Profile Views
Build and Export Lists of

PE Backed Companies
Direct Investors & Acquirers
Advisors
Deals
& More

Get Full Access

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore a company's M&A activity, ownership history, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

Stay informed on events in your industry
M&A research that takes seconds (not all afternoon)
Better understand your customers and prospects
Discover active buyers (or sellers)

Search

4.7K Private Equity Firms
208K M&A Transactions
210K Companies Involved in M&A
(Buyer, Seller, or Target)
3.7K M&A Advisors
(Investment Banks and Law Firms)
81K M&A Contacts
(PE and M&A Advisors)

What next?

Get Full Access

Full access to Mergr's investor, acquirer, and transaction data starts here.

Related Lists for iBio - Preclinical PD-1 Agonist Antibody Program

Life Science Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies